Cost of therapy for cystic fibrosis in different age groups with consideration to the respiratory tract infection and complications
https://doi.org/10.18093/0869-0189-2021-31-2-238-249
Abstract
Despite the low prevalence of cystic fibrosis (CF), the costs of treating this disease are significant for the healthcare system. The aim of this economic study was to assess the total cost of drugs per year for children with CF, depending on age and course of the disease.
Methods. For this pharmacoeconomic analysis, groups of “hypothetical” patients were formed according to the characteristics of the course of CF, taking into account the required volume of basic CF therapy, antibiotic therapy, and complications.
Results. The cost of basic treatment for CF patients of different ages and disease progression in the hypothetical patient models can vary greatly. The cost of CF therapy increases significantly with age and Pseudomonas aeruginosa respiratory infection, especially in the patients with chronic infection, concomitant polyposis sinusitis, and low nutritional status.
Conclusion. Patients with CF require regular follow-up with control of the microflora of the respiratory tract and effective eradication therapy for P. aeruginosa and other pathogenic microorganisms. Reducing infection rates and the severity of the disease can lead to significant cost savings.
About the Authors
E. G. Furman
Аcademician E.A.Vagner Perm’ State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests:
Russian Federation
Evgeniy G. Furman, Doctor of Medicine, Professor, Head of the Department of Faculty and Hospital Pediatrics.
ul. Petropavlovskaya 26, Perm’, 614990, Russia; tel.: (342) 221-86-15
Competing Interests:
The authors did not declare any conflicts of interest
V. V. Shadrina
Аcademician E.A.Vagner Perm’ State Medical University, Healthcare Ministry of Russia
Russian Federation
Competing Interests:
Russian Federation
Vera V. Shadrina, Candidate of Medicine, Associate Professor, Department of Faculty and Hospital Pediatrics.
ul. Petropavlovskaya 26, Perm’, 614990, Russia; tel.: (342) 221-86-15
Competing Interests:
The authors did not declare any conflicts of interest
T. Yu. Maksimycheva
Federal State Budgetary Scientific Institution “Research Center for Medical Genetics”
Russian Federation
Competing Interests:
Russian Federation
Tat’yana Yu. Maksimycheva, Researcher, Scientific and Clinical Department of Cystic Fibrosis.
Russian Academy of Science: ul. Moskvorech’e 1, Moscow, 1115478, Russia; tel.: (499) 959-86-96
Competing Interests:
The authors did not declare any conflicts of interest
V. D. Sherman
Federal State Budgetary Scientific Institution “Research Center for Medical Genetics”
Russian Federation
Competing Interests:
Russian Federation
Viktoriya D. Sherman, Candidate of Medicine, Leading Researcher, Research and Clinical Division of Cystic Fibrosis.
Russian Academy of Science: ul. Moskvorech’e 1, Moscow, 1115478, Russia; tel.: (916) 188-24-76
Competing Interests:
The authors did not declare any conflicts of interest
E. I. Kondratyeva
Federal State Budgetary Scientific Institution “Research Center for Medical Genetics”
Russian Federation
Competing Interests:
Russian Federation
Elena I. Kondratyeva, Doctor of Medicine, Professor, Head of Research and Clinical Division of Cystic Fibrosis, Head of Cystic Fibrosis Department.
Russian Academy of Science: ul. Moskvorech’e 1, Moscow, 1115478, Russia; tel.: (495) 111-03-03
Competing Interests:
The authors did not declare any conflicts of interest
References
1. Scotet V., L’Hostis C., Férec C. The changing epidemiology of cystic fibrosis: Incidence, survival and impact of the CFTR gene discovery. Genes. 2020; 11 (6): 589. DOI: 10.3390/genes11060589.
2. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020; 109 (5): 893–899. DOI: 10.1111/APA.15155.
3. Kapranov N.I., Kashirskaya N.Yu., ed. [Cystic Fibrosis]. Moscow: Medpraktika-M; 2014 (in Russian).
4. Amelina E.L., Kashirskaya N.Yu., Kondratyeva E.I. et al., eds. [Russian Federation cystic fibrosis patients Registry. 2018 year]. Moscow: Medpraktika-M; 2020. Available at: https://mukoviscidoz.org/doc/registr/web_block_Registre_2018.pdf (in Russian).
5. Cystic Fibrosis Foundation Patient Registry. 2018 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2019. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf
6. Krasovskiy S.A., Chernyak A.V., Kashirskaya N.Yu. et al. [Cystic fibrosis in Russian Federation: the establishment of the National Registry]. Pediatriya. Zhurnal im. G.N.Speranskogo. 2014; 93 (4): 44–55 (in Russian).
7. Kondratyeva E.I., Kashirskaya N.Yu., Kapranov N.I., eds. [National consensus “Cystic fibrosis: definition, diagnostic criteria, therapy”]. Moscow: Borges; 2016. Available at: http://ostrovaru.com/biblioteka/Chiesi_consensus_new_A4.pdf (in Russian).
8. Kondratyeva E.I., Kashirskaya N.Yu., Kapranov N.I., eds. [National consensus “Cystic fibrosis: definition, diagnostic criteria, therapy”]. Moscow: Borges; 2018 (in Russian).
9. [Cystic fibrosis: clinical guidelines. 2020]. Available at: http://cr.rosminzdrav.ru/schema/372 (in Russian).
10. Kashirskaya N.Yu., Kapranov N.I., Vasil’eva Yu.I. [Pharmacoeconomic effectiveness of some modern methods of therapy in cystic fibrosis children]. Pediatricheskaya farmakologiya. 2006; 3 (3): 32–37. Available at: https://cyberleninka.ru/article/n/farmakoekonomicheskaya-effektivnost-nekotoryh-sovremennyh-metodov-terapii-u-detey-s-mukovistsidozom/viewer (in Russian).
11. Gu Y., García-Pérez S., Massie J., van Gool K. Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data. Eur. J. Health Econ. 2015; 16 (7): 709–717. DOI: 10.1007/s10198-014-0621-5.
12. Jackson A.D., Jackson A.L., Fletcher G. et al. Estimating direct cost of cystic fibrosis care using Irish registry healthcare resource utilisation data, 2008–2012. Pharmacoeconomics. 2017; 35 (10): 1087–1101. DOI: 10.1007/s40273-017-0530-4.
13. Smith A., Barry M. Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database. BMJ Open. 2020; 10 (11): e040806. DOI: 10.1136/bmjopen-2020-040806.
14. Heimeshoff M., Hollmeyer H., Schreyögg J. et al. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics. 2012; 30 (9): 763–777. DOI: 10.2165/11588870-000000000-00000.
15. van Gool K., Norman R., Delatycki M.B. et al. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health. 2013; 16 (2): 345–355. DOI: 10.1016/j.jval.2012.12.003.
16. Maksimycheva T.Yu., Kondratyeva E.I., Budzinskiy R.M. et al. [Analysis of the cost of treatment for exacerbations of children with cystic fibrosis depending on the nutritional status]. Rossiyskiy vestnik perinatologii i pediatrii. 2018; 63: (4): 148. DOI: 10.21508/1027-4065-congress-2018 (in Russian).
17. Yagudina R.I., Litvinenko M.M. [Cost of illness analysis as a basic method of pharmacoeconomic study of the different levels of the health care system]. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2014; (1): 55–59. Available at: https://cyberleninka.ru/article/n/analiz-stoimosti-bolezni-kak-bazovyy-metod-farmakoekonomicheskih-issledovaniy-razlichnyh-urovney-sistemy-zdravoohraneniya/viewer (in Russian).
18. Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu. et al., eds. [Registry of patients with cystic fibrosis in the Russian Federation. 2017]. Moscow: Medpraktika-M; 2019 (in Russian).
19. [Cystic fibrosis in children: Clinical guidelines. 2016]. Available at: http://astgmu.ru/wp-content/uploads/2018/10/Kistoznyj-fibroz-mukovistsidoz-u-detej-2016.pdf (in Russian).
20. Yagudina R.I., Serpik V.G. [Methodology of cost analysis]. Farmakoekonomika: Teoriya i praktika. 2016; 4 (2): 3–14 (in Russian).
21. Amelina E.L., Kondratyeva E.I., Krasovskiy S.A. et al. [Inhaled combination of 7% hypertonic saline and 0.1% hyaluronic acid in therapy of patients with cystic fibrosis: results of a Russian observational study]. Pul’monologiya. 2018; 28 (4): 436–444. DOI: 10.18093/0869-0189-2018-28-4-436-444 (in Russian)
22.
Review
For citations:
Furman E.G., Shadrina V.V., Maksimycheva T.Yu., Sherman V.D., Kondratyeva E.I. Cost of therapy for cystic fibrosis in different age groups with consideration to the respiratory tract infection and complications. PULMONOLOGIYA. 2021;31(2):238-249. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-2-238-249
Views:
663
Email this article 